Zobrazeno 1 - 10
of 1 284
pro vyhledávání: ''
Autor:
Shotaro Suzuki, Hiroko Nagafuchi, Yutaka Goto, Keiichi Sakurai, Yoshioki Yamasaki, Kimito Kawahata, Tomohiko Shibata, Mitsuru Imamura, Takeshi Suzuki
Publikováno v:
Modern Rheumatology. 31:1087-1093
ObjectivesRheumatoid arthritis (RA) in patients undergoing immunosuppressive therapy (IS) is sometimes involved with other iatrogenic immunodeficiency-associated lymphoproliferative disorders (LPD). We aimed to clarify the effects of LPD treatment on
Autor:
Yasuhiko Ito, Hirokazu Sugiyama, Satoru Ito, Akihito Kubo, Shiho Iwagaitsu, Takayuki Katsuno, Hiroshi Kinashi, Hironobu Nobata, Makoto Yamaguchi, Shogo Banno, Etsuro Yamaguchi
Publikováno v:
Modern Rheumatology Case Reports. 6:1-5
A 53-year-old woman diagnosed with rheumatoid arthritis (RA) demonstrated thick-walled large cavities with consolidation in the left upper lobe on chest computed tomography (CT). Mycobacterium avium was isolated from sputum cultures, and she was diag
Autor:
Frank X Liu, Nicole Fulcher, Stan Krulewicz, Jodi Smith, Marley Boyd, Abhijeet Bhanegaonkar, C. Lance Cowey, Ruth Kim
Publikováno v:
The Oncologist
Background Immunotherapy (IO) has been associated with improved outcomes in patients with locally advanced Merkel cell carcinoma (laMCC) and metastatic Merkel cell carcinoma (mMCC). The primary objective of SPEAR‐Merkel was to explore treatment pat
Autor:
Chinatsu Mori, Masato Ozaka, Naoki Sasahira, Takashi Sasaki, Yuto Yamada, Takeshi Okamoto, Masato Matsuyama, Takafumi Mie, Tsuyoshi Takeda, Akiyoshi Kasuga, Takaaki Furukawa
Publikováno v:
Japanese Journal of Clinical Oncology. 51:1416-1422
Objective With the introduction of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel therapy for unresectable pancreatic cancer, erlotinib plus gemcitabine therapy is now occasionally used as late-line therapy. This study investigates outcomes
Autor:
Michael Ong, Jean-Michel Lavoie, Nimira S. Alimohamed, Bernhard J. Eigl, Srikala S. Sridhar, Deanna McLeod, Scott North
Publikováno v:
The Oncologist
Background Metastatic urothelial carcinoma (mUC) historically is treated with first‐line platinum‐based combination chemotherapy, preferably cisplatin plus gemcitabine whenever possible. In recent years, multiple classes of targeted therapy have
Publikováno v:
Oncologist
Perioperative chemotherapy is standard treatment for patients with early high‐risk gastroesophageal adenocarcinoma independent of molecular subtype. Approximately 8% of gastroesophageal cancers have a microsatellite instable phenotype (MSI‐H), an
Autor:
Xin Wang, Feng Bi, Hongfeng Gou, Qiu Li, Ye Chen, Ji-Yan Liu, Zhiping Li, Ke Cheng, Yali Shen, Yu Yang, Dan Cao, Deyun Luo, Meng Qiu, Yuwen Zhou
Publikováno v:
Oncologist
Lessons Learned Background In patients with metastatic colorectal cancer (mCRC) refractory to standard therapies, S-1 plus raltitrexed showed a good objective response rate (ORR) and significant survival benefit in our previous study. In the present
Publikováno v:
Oncologist
Background Irinotecan (CPT11) is an important drug for small cell lung cancer (SCLC) chemotherapy (CTx). UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphisms can influence CPT11-related toxicity. This study aimed to assess prevalence of UGT1A1 poly
Autor:
Annette M. Molinaro, Jennie Taylor, Anny Shai, Joanna J. Phillips, Serah Choi, Stephanie Hilz, Tali Mazor, Mitchel S. Berger, Bruce H Wainer, David A. Solomon, Susan M. Chang, Michael W. McDermott, Nancy Ann Oberheim Bush, Yao Yu, Daphne A. Haas-Kogan, Nicholas Butowski, Chibo Hong, Jennifer Clarke, Michael Wahl, Joseph F. Costello, Javier Villanueva-Meyer, Matthew R. Grimmer
Publikováno v:
Neuro-oncology, vol 23, iss 11
Neuro Oncol
Neuro Oncol
Background Chemotherapy improves overall survival after surgery and radiotherapy for newly diagnosed high-risk IDH-mutant low-grade gliomas (LGGs), but a proportion of patients treated with temozolomide (TMZ) will develop recurrent tumors with TMZ-in
Publikováno v:
J Natl Cancer Inst
Background Chemotherapy-induced premature menopause leads to some consequences, including infertility. We initiated this randomized phase III trial to determine whether a cyclophosphamide-free adjuvant chemotherapy regimen would increase the likeliho